Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
National HealthcareFRA:HTW -2.11%71 3-Year EBITDA Growth Rate is 45.70% as of Jun. 2026, which is 1043% above its 10-year median of 4.00. GuruFocus rates FRA:HTW with a GF Score™ of 71/100 and a GF Value™ of €111.35. The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, National Healthcare ranks better than 88.59% on this metric.
During the past 12 months, National Healthcare's average EBITDA Per Share Growth Rate was 20.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 45.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 2.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of National Healthcare was 45.70% per year. The lowest was -21.60% per year. And the median was 4.00% per year.
National Healthcare (FRA:HTW) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
National Healthcare 3-Year EBITDA Growth Rate Related Terms
FRA:HTW vs BKD, OPCH, ACHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, National Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
National Healthcare 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, National Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where National Healthcare's 3-Year EBITDA Growth Rate falls into.
National Healthcare 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 45.70% mean?
National Healthcare (FRA:HTW) has a 3-Year EBITDA Growth Rate of 45.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for National Healthcare and its competitors. This is 1043% above median its historical median of 4.00. According to the industry distribution chart, National Healthcare ranks #60 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 11.4%.
Is National Healthcare's 3-Year EBITDA Growth Rate too high?
National Healthcare's current 3-Year EBITDA Growth Rate of 45.70% is 1043% above median its 10-year median of 4.00. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. National Healthcare's value of 45.70% is 348% above this industry median. Based on the distribution chart, National Healthcare ranks #60 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, National Healthcare has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does National Healthcare's 3-Year EBITDA Growth Rate compare to BKD and OPCH?
According to the Healthcare Providers & Services industry distribution chart, National Healthcare ranks #60 out of 526 companies for 3-Year EBITDA Growth Rate. This places National Healthcare in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. National Healthcare's value of 45.70% is 348% above this benchmark. While the company's 10-year median is 4.00 vs. the industry median of 10.20, National Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. National Healthcare's current 3-Year EBITDA Growth Rate of 45.70% is 348% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for National Healthcare and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. National Healthcare's current 3-Year EBITDA Growth Rate is 45.70%, which is 1043% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is National Healthcare stock overvalued right now?
National Healthcare (FRA:HTW) has a current 3-Year EBITDA Growth Rate of 45.70%. The stock's GF Value™ is €111.35, compared to a current price of €186.00 — trading 67% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 45.70%, which is 1043% above median its 10-year median of 4.00 and 348% above the Healthcare Providers & Services industry median of 10.20. National Healthcare's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For National Healthcare (FRA:HTW), the current 3-Year EBITDA Growth Rate is 45.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is National Healthcare (FRA:HTW) Overvalued in 2026?
Based on GuruFocus' analysis, National Healthcare stock appears to be overvalued.
The current stock price of €186.00 is trading 67% above its estimated GF Value™ of €111.35.
Key valuation signals for FRA:HTW:
3-Year EBITDA Growth Rate: 45.70% (1043% above median its 10-year median of 4.00)
GF Value™: €111.35 vs. price of €186.00 (67% above fair value)
Industry Position: 348% above the Healthcare Providers & Services median (#60 of 526)
No single metric tells the full story. See the FRA:HTW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
National Healthcare Corp provides long-term care facilities. Its principal business includes operating skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services and Home care and hospice services. The majority of revenue is derived from the Inpatient services segment.
71GF Score
Get the complete analysis for FRA:HTW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTW has been successfully added to your 
